Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects
Abstract
The overall objective is to provide proof-of-principle that recombinant human relaxin (rhRLX) administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesis/vasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated: reproducible implementation of uniform cranial lesions of ~1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ng/ml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice (~50 ).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2017
- Accession Number
- AD1051151
Entities
People
- Kirk P Conrad
Organizations
- University of Florida